Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR
Researchers at Boston Biomedical, Inc., are working to develop a novel first-in-class cancer drug that works by targeting the stem like properties of some cancer cells, and so far, results of an ongoing Phase I clinical trial demonstrate early signs of a strong safety profile and clinical activity.

Read more on News-Medical-Net